Pre-Weaning Respiratory Disease Studied in Beef Calves

Why It Matters

This evidence suggests that early coronavirus vaccination can cut treatment costs, improve weight gain, and reduce death loss in beef calf operations, offering a tangible tool for producers facing persistent pre‑weaning BRD.

Key Takeaways

• Intranasal coronavirus vaccine reduced BRD treatments from 22% to 16%
• Treated calves showed 2 kg higher weaning weight
• Mortality decreased in second birth cycle after vaccination
• Study involved 887 calves across two groups
• Vaccine not approved for intranasal use but showed efficacy

Pulse Analysis

Bovine respiratory disease (BRD) remains the leading cause of mortality in feedlot cattle, and most scientific attention has centered on the post‑weaning “shipping fever” that strikes stressed, transported calves. Yet a comparable, often overlooked, wave of pneumonia hits nursing beef calves older than three weeks, driving early‑life losses on cow‑cattle operations. The scarcity of field trials in this segment leaves producers without evidence‑based vaccination protocols, prompting researchers to explore whether targeting viral contributors such as bovine coronavirus can shift the disease dynamics before calves even leave the pasture.

In the Canadian Veterinary Journal, Dr. Nathan Erickson and colleagues described a randomized trial with 887 mixed‑breed calves on an Alberta ranch that had recurring BRD in calves 10‑50 days old. Calves received an intranasal dose of a modified‑live bovine coronavirus/rotavirus vaccine within 24 hours of birth, while controls followed the standard IBR, PI3 and BRSV regimen. The vaccinated group required treatment for respiratory disease in 16 % of animals versus 22 % in controls, a statistically significant reduction. Treated calves also weighed about two kilograms more at weaning and showed lower mortality in the second birth cycle.

From a business perspective, a 6‑percentage‑point drop in treatment incidence translates into measurable cost savings on antibiotics, labor, and veterinary visits, while the extra kilogram of gain improves feed‑efficiency and market weight. However, producers must weigh the off‑label intranasal use of a coronavirus‑rotavirus vaccine against regulatory considerations and the need for herd‑specific risk assessments. The findings encourage further multi‑site trials to confirm efficacy across diverse climates and management systems, and they reinforce the role of early‑life viral immunization as part of an integrated BRD control program. Veterinarians remain essential partners in tailoring vaccine schedules to each operation.